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Abstract
Aims/hypothesis Variation in fasting plasma glucose (FPG)
within the normal range is a known risk factor for the
development of type 2 diabetes. Several reports have shown
that genetic variation in the genes for glucokinase (GCK),
glucokinase regulatory protein (GCKR), islet-specific glu-
cose 6 phosphatase catalytic subunit-related protein
(G6PC2) and melatonin receptor type 1B (MTNR1B)i s
associated with FPG. In this study we examined whether
these loci also contribute to type 2 diabetes susceptibility.
Methods A random selection from the Dutch New Hoorn
Study was used for replication of the association with FGP
(2,361 non-diabetic participants). For the genetic association
study we extended the study sample with 2,628 participants
with type 2 diabetes. Risk allele counting was used to
calculate a four-gene risk allele score for each individual.
Results VariantsoftheGCK, G6PC2 and MTNR1B genes but
not GCKR were associated with FPG (all, p≤0.001; GCKR,
p=0.23). Combining these four genes in a risk allele score
resulted in an increase of 0.05 mmol/l (0.04–0.07) per
additional risk allele (p=2×10
−13). Furthermore, participants
with less than three or more than five risk alleles showed
significantly different type 2 diabetes susceptibility compared
with the most common group with four risk alleles (OR 0.77
[0.65–0.93], p=0.005 and OR 2.05 [1.50–2.80], p=4×10
−6
respectively). The age at diagnosis was also significantly
associated with the number of risk alleles (p=0.009).
Conclusions A combined risk allele score for single-
nucleotide polymorphisms in four known FPG loci is
significantly associated with FPG and HbA1c in a Dutch
population-based sample of non-diabetic participants. Car-
riers of low or high numbers of risk alleles show
significantly different risks for type 2 diabetes compared
with the reference group.
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DCS Diabetes Care System West Friesland
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Introduction
Variation in fasting plasma glucose (FPG) levels within the
normal range are associated with an increased risk of
developing type 2 diabetes and coronary heart disease [1, 2].
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Amsterdam, the NetherlandsFurthermore, it is known that FPG is partially genetically
determined [3]. Several loci influencing FPG levels have
been identified. These loci encode glucokinase (GCK),
glucokinase regulatory protein (GCKR) and islet-specific
glucose 6 phosphatase catalytic subunit-related protein
(G6PC2)[ 4–10]. Recently, the gene encoding melatonin
receptor type 1B (MTNR1B) was identified as a fourth locus
influencing FPG [11–13]. In this study we investigated the
combinedeffectoftheselocionFPGlevelsintheNetherlands
and analysed their single and combined effects on the risk of
type 2 diabetes.
Methods
Study samples
Study sample for continuous trait analysis For this part of
the study we used participants from the ongoing New
Hoorn Study, a population-based cohort study in the
Netherlands, which examines potential determinants of
glucose intolerance and related disorders [14, 15]. From
this study, 2,361 non-diabetic white participants (46% male,
aged 53±7 years) were selected from the original random
sample of the population register of the town of Hoorn, the
Netherlands. Glucose tolerance status was assessed with
OGTTs using the 1999 WHO criteria [16].
Case–control sample for genetic association with type 2
diabetes As a control sample we used all participants with
normal glucose tolerance from the above-mentioned sample
(n=2,041). Subjects with impaired glucose tolerance (IGT)
and/or impaired fasting glucose (IFG; n=320) were
excluded from the control group because they have an
increased risk of type 2 diabetes.
For the case sample we used all known (n=90) and
newly identified (n=90) cases from the New Hoorn Study.
To improve power we added cases from Diabetes Care
System West Friesland (DCS, n=1,906) [17]. The DCS
aims to improve diabetes care by coordinating diabetes
care, involving all caregivers and providing education for
patients in order to improve patient empowerment. Patients
are referred to the DCS by their physicians and are from the
same geographical region as those taking part in the New
Hoorn Study. We also included 542 type 2 diabetes patients
from the diabetes clinics at Leiden University Medical
Centre (Leiden, the Netherlands) and VU University
Medical Centre (Amsterdam, the Netherlands), who were
referred to the clinic by their physicians. In total we
selected 2,628 participants with type 2 diabetes (55%
males, aged 64±11 years) for the case–control study. All
participants in our study were of white ethnicity. The study
was approved by the appropriate medical ethics committees
and was in accordance with the principles of the Declara-
tion of Helsinki.
Genotyping and quality control
Based on previous publications, we selected the single-
nucleotide polymorphisms (SNPs) rs1799884 in GCK [4],
rs1260326 (P446L) in GCKR [7], rs560887 in G6PC2 [9]
and rs10830963 in MTNR1B [11–13] for genotyping with
Taqman SNP genotyping assay (Applied Biosystems,
Foster City, CA, USA). All genotype frequencies were
similar between the case subgroups. For quality control the
allelic discrimination plots were visually observed for good
clustering. Plates with bad clustering or a success rate
below 95% were repeated. Next, we assessed Hardy–
Weinberg equilibrium (p>0.05) and genotyped approxi-
mately 5% duplicate samples, which all showed identical
genotypes.
Statistical analysis
Differences in FPG and other clinical variables (HbA1c,2h
glucose, triacylglycerol, LDL, HDL, total cholesterol, BMI
and waist–hip ratio) were analysed in non-diabetic partic-
ipants using linear regression, adjusted for BMI, age and
sex as possible confounders. All analyses were performed
using an additive model, because previous studies had
shown that this model was the best fit. In order to combine
the effects of all SNPs, risk alleles were counted and used
as a sum score [18]. A risk allele was defined as an allele
that results in an increased FPG as described in the
literature. Differences in genotype distribution, allele
frequency and risk allele scores between participants with
normal glucose tolerance and those with type 2 diabetes
were compared using standard contingency tables with
Fisher’s exact test, and allelic ORs were calculated with
logistic regression adjusted for age, sex and BMI. Subjects
with either IGT or IFG were excluded from this analysis.
Using Bonferroni correction for multiple hypothesis testing,
p<0.001 was considered statistically significant for associ-
ation of FPG loci with clinical variables (36 tests). For the
case–control study, p<0.01 was considered significant (four
tests). All statistics were calculated using SPSS 16.0 (SPSS,
Chicago, IL, USA).
Power calculations
Power calculations were performed using Quanto [19]. We
had an estimated power of 80% to detect a minimal per
allele effect in clinical variables between 0.056 and
0.069 mmol/l, depending on allele frequency (α=0.001).
For the association study with type 2 diabetes we had an
Diabetologia (2009) 52:1866–1870 1867estimated power of 80% to detect a minimal OR between
1.13 and 1.16 for single gene effects (α=0.01). For all
power calculations we assumed an additive model.
Results
All SNPs passed quality control guidelines. Associations
between SNPs and clinical variables were analysed in the
non-diabetic participants only. Results of association with
FPG levels were comparable to those reported in the
literature (all p≤0.001), except for GCKR, for which we
could not detect a significant effect on FPG levels (p=0.23;
r e s u l t ss h o w ni nT a b l e1). However, GCKR showed
nominal evidence for decreased 2 h glucose, but did not
reach a formally significant p value (p=0.008; see
Electronic supplementary material [ESM] Table 1). Fur-
thermore, GCK and G6PC2 showed increased HbA1c levels
(p=5×10
−8 and 3×10
−5; ESM Table 1). In line with our
FPG results, GCKR was not associated with HbA1c levels
(p=0.50). However, we did confirm the previously reported
association of the T allele of rs1260326 (GCKR) with
increased triacylglycerol levels (p=9×10
−7; ESM Table 1)
[5]. Other clinical variables were not associated with any of
the analysed variants (ESM Table 1). We analysed the
combined effect of all SNPs by calculating the risk allele
score for each individual. We observed a combined effect of
the risk alleles on FPG levels. The increase in FPG level
per additional risk allele was 0.05 (0.04–0.07) mmol/l,
p=2×10
−13 (Fig. 1a). A similar result was observed for
HbA1c: 0.03% (0.02–0.04%) increase per additional risk
allele, p=5×10
−10 (Fig. 1b). We also analysed whether the
rate of the age-related increase in FPG was affected by the
number of risk alleles. However, we did not observe any
divergence in these rates between the different risk allele
scores in our cross-sectional data set (ESM Fig. 1). Separate
analysis of only the participants with normal glucose
tolerance (n=2,041) did not alter any of the results (data
not shown).
Next, we analysed the association of the single gene
variants and the risk allele score with type 2 diabetes
susceptibility. Only rs10830963 (MTNR1B) and rs1799884
(GCK) showed weak evidence for association with type 2
diabetes (p=0.02 and p=0.06 respectively; Table 1 and
ESM Table 2). Risk allele scores were calculated for the
participants with normal glucose tolerance and those with
type 2 diabetes and all risk allele groups were compared
with the reference group having four risk alleles, since this
was the most common group (31%). The lower risk allele
groups showed a protective effect on type 2 diabetes, while
the risk allele groups with more than four risk alleles
showed an increased risk of type 2 diabetes (Table 2).
Those with fewer than three risk alleles had a significantly
reduced risk of type 2 diabetes (OR 0.77 [0.65–0.93],
p=0.005) whereas those with more than five had a signif-
icantly increased risk of type 2 diabetes compared with the
reference group (OR 2.05 [1.50–2.80], p=4×10
−6). Adjust-
ment for age, sex and BMI did not alter the results.
We also noted a significant correlation with the age at
diagnosis of type 2 diabetes in our study sample. We
observed a per allele effect of −0.46 (−0.80 to −0.11) years
in age at diagnosis per additional risk allele (p=0.009;
Table 1 Association of SNPs with FPG (n=2,361) and type 2 diabetes (n=4,669)
SNP Locus Risk allele FPG, mmol/l (genotype count) Effect per allele,
mmol/l (95% CI)
p value T2D OR p value
AA AB BB 95% CI
rs1799884 GCK A 5.39±0.01
(1,523)
5.45±0.02
(620)
5.47±0.05
(65)
0.06
(0.03, 0.09)
0.001 1.12
(1.00, 1.25)
0.06
rs1260326 GCKR C 5.35±0.03
(267)
5.39±0.01
(956)
5.38±0.01
(924)
0.01
(−0.02, 0.03)
0.23 0.94
(0.86, 1.02)
0.13
rs560887 G6PC2 G 5.32±0.03
(218)
5.36±0.01
(930)
5.43±0.01
(1,077)
0.06
(0.04, 0.09)
5×10
−6 0.96
(0.87, 1.05)
0.32
rs10830963 MTNR1B G 5.37±0.01
(1,269)
5.44±0.01
(891)
5.52±0.04
(135)
0.08
(0.05, 0.11)
7×10
−8 1.12
(1.02, 1.23)
0.02
Estimated FPG levels (mean±SD) per genotype are adjusted for age, sex and BMI
Effect per allele on FPG levels and p values, adjusted for age, sex and BMI, were generated by linear regression
Because of differences in the number of participants genotyped for each of the loci, the estimated means are slightly different
The B genotype represents the risk allele
Odds ratios are for associations of independent SNPs with type 2 diabetes and were calculated based on allele frequency in 2,041 controls and
2,628 type 2 diabetes participants
Subjects with IGT or IFG were excluded from this analysis
T2D, type 2 diabetes
1868 Diabetologia (2009) 52:1866–1870Table 2). At the extremes of the distribution, i.e. zero or
one vs six to eight risk alleles, there was a difference of
almost 4.5 years in age at diagnosis between the two
groups (p=0.002; Table 2).
Discussion
Several studies have shown that SNPs in GCK, GCKR,
G6PC2 and MTNR1B are associated with FPG levels [4–7,
9, 11–13, 20]. In this study we replicated these findings in a
Dutch population, with the exception of the association of
GCKR with FPG. However, our results for GCKR are in the
same direction as those of most other studies and it should
be noted that some other recent publications reported
considerable variability in effect size between different
samples [8] or failed to replicate this observation [11]. GCK
and G6PC2 were associated with HbA1c in our study,
which confirms previous observations [13, 21].
We observed a significant combined effect of all variants
on FPG levels. This confirms a recent observation in a
French study [13]. The association of FPG levels with the
risk allele count was also reflected in increased HbA1c
levels, arguing against previous findings in which it was
suggested that FPG and HbA1c have independent underly-
ing risk loci [22, 23]. Our cross-sectional data suggest that
these loci cause a physiological disturbance of glucose
homeostasis by raising the set point of insulin secretion,
leading to an elevation of FPG depending on the number of
risk alleles present, which is not further affected by ageing.
However, longitudinal studies and a wider age span would
be needed to confirm this observation.
To our knowledge, this is the first report showing that
the analysed loci have a combined effect on type 2 diabetes
susceptibility, although the contribution of each individual
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Fig. 1 Combined effect of GCK, GCKR, G6PC2 and MTNR1B on
FPG and HbA1c in non-diabetic participants from the New Hoorn
Study. a Fasting plasma glucose. Numbers within the bars are
numbers of participants per allele group. The per allele effect was
0.05 (0.04–0.07) mmol/l, p=2×10
−13. Error bars represent 95% CI.
b HbA1c. Numbers within the bars represent the number of
participants per allele group. The per allele effect was 0.03% (0.02–
0.04%), p=5×10
−10 Error bars represent 95% CI
Table 2 Association of risk allele scores with type 2 diabetes
Alleles Count (frequency) Age at diagnosis
a (years, mean±SD) OR for T2D (95% CI) p value OR for T2D
Controls (n=2,041) Cases (n=2,628)
0 or 1 76 (4.2) 115 (4.9) 57.5±1.1 0.75 (0.55–1.02) 0.07
2 243 (13.5) 352 (15.0) 57.3±0.6 0.78 (0.64–0.95) 0.02
3 522 (29.0) 667 (28.4) 56.1±0.5 0.89 (0.76–1.04) 0.14
4 605 (33.6) 685 (29.1) 55.6±0.4 1.00 ref
5 288 (16.0) 381 (16.2) 56.1±0.6 1.17 (0.97–1.41) 0.11
6–8 65 (3.6) 151 (6.4) 52.9±0.9 2.05 (1.50–2.80) 4×10
−6
aAge at diagnosis was available for 2,132 participants with type 2 diabetes
βage at diagnosis=−0.46 (−0.80 to −0.11) years, p=0.009 adjusted for sex
The OR for type 2 diabetes and p value were compared with the four risk alleles group as a reference (ref)
The OR for type 2 diabetes for less than three vs four risk alleles was 0.77 (0.65–0.93), p=0.005 and the OR for type 2 diabetes for more than four
vs four risk alleles was 1.33 (1.12–1.58), p=0.001
T2D, type 2 diabetes
Diabetologia (2009) 52:1866–1870 1869variant to the risk of type 2 diabetes is very low or
undetectable (Table 1). Our data show that carriers of fewer
than three risk alleles are at decreased risk of type 2
diabetes whereas those with more than five risk alleles have
increased susceptibility to type 2 diabetes compared with
the most common risk allele group of four risk alleles. We
also noted a significantly different age at diagnosis between
the different groups, indicating that the number of risk
alleles also influences the age at which the disease becomes
manifest. This might also have implications for the
development of complications. If replicated, our results
imply that these loci not only influence FPG levels,
probably through an altered set point for glucose at which
an insulin response is elicited, but also jointly increase the
risk of type 2 diabetes and the age at diagnosis.
In conclusion, we replicated the combined effect of
GCK, GCKR, G6PC2 and MTNR1B risk alleles with FPG.
Furthermore, we showed that the risk allele score is also
associated with HbA1c and that carriers of a low or high
number of risk alleles have significantly different suscepti-
bilities to the development of type 2 diabetes and age at
diagnosis of the disease.
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